Safety and Effectiveness of Anti Inhibitor Coagulation Complex (AICC) in Routine Clinical Management: a Post-Authorization Safety Study (PASS)
Bleeding Risk for the Active Person with Hemophilia: A Comparison of Factor VIII Treatment Regimens
Background: Bleeding risk during physical activities for persons with hemophilia has been shown to be reduced with adequate factor levels (Broderick 2012). With extended half-life Factor VIII and IX products offering…
The Impact of Reduced Treatment Frequency: Qualitative Evaluation of Adherence and Outcomes in Chronic Disease Management
The expression of codon-optimized blood coagulation factor VIII using a lentiviral system
Using Oral History for Patient Education: The Gift of Experience II: Conversations with Parents about Hemophilia
New insights from modeling FVIII Kinetics of Native vs. Extended Half-life FVIII Products - Comparing FVIII Coverage under Various Dosing Scenarios
Introduction: Extended half-life factor VIII (FVIII) products currently in development require a careful evaluation of dosing options given that the pharmacokinetics of weekly FVIII levels , including FVIII peak and trough levels…
The use of combination therapy with plasma derived and recombinant factor VIII in patients with hemophilia A: a single institution experience
Ongoing Prospective ADVATE Immune Tolerance Induction Registry (PAIR) Continues to Demonstrate Success Rates Consistent with Published Literature
Objectives: PAIR is an ongoing, global, non-interventional, post-authorization safety surveillance designed to collect information on ADVATE safety and effectiveness in immune tolerance induction (ITI) therapy in routine practice…
Real World Utilization and Cost of aPCC versus rFVIIa Among Hemophilia Patients with Inhibitors in the US
Introduction and Objective: Limited information exists in the recent literature capturing real- world utilization and cost of bypassing agents among hemophiliac patients with inhibitors in the US. The present study compared the…
Pain and Arthropathy Impact Quality of Life of Young Adults With Hemophilia (ages 18-30) in the United States: Observations From the Hemophilia Experiences, Results and Opportunities (HERO) Study
Objective: To assess quality of life, self-reported comorbidities, health-related quality of life (HRQoL), and impact of hemophilia on activities of young adult (YA) patients with hemophilia (PWH). Methods:…